Mumbai. On Wednesday (11 December), the Indian regulator Central Drugs Standard Control Organization (CDSCO) has approved the country's renowned pharmaceutical company Cipla for the distribution and marketing of inhaled insulin in the country.

According to the information, the insulin called Afrezza is created and manufactured by MannKind Corporation, and is used to improve glycemic control in adults with diabetes mellitus.

Diabetes patients will get help.

Cipla company said that Afrezza is a fast-acting insulin that is given through an inhaler. Currently, insulin is given in the form of injection. This is taken at the beginning of the meal. Afrezza dissolves quickly in the lungs and delivers insulin to the blood quickly.

The effect will be visible in just 12 minutes.

Cipla aims to make the drug accessible to all and enable millions of people to take control of their health more easily. The company claims that it will start working in just 12 minutes and will help reduce the sharp increase in sugar levels seen with food.

Beneficial for diabetes type 1 and type 2 patients

The company has claimed that the effect of Afrezza lasts for about two to three hours in the body and it leaves a very similar effect as insulin. The company said that this is the first and only non-injectable insulin developed for patients with both type 1 and type 2 diabetes mellitus.